Alector, Inc. Files Q3 2024 10-Q Report
Ticker: ALEC · Form: 10-Q · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Alector's Q3 2024 10-Q is in. Check financials.
AI Summary
Alector, Inc. filed its Q3 2024 10-Q report on November 6, 2024, detailing its financial performance and operations for the period ending September 30, 2024. The company, focused on biological products, is based in South San Francisco, CA. Key financial data and operational updates are presented in this filing.
Why It Matters
This filing provides investors and stakeholders with an update on Alector's financial health and operational progress during the third quarter of 2024, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a biotechnology company, Alector faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the sector.
Key Numbers
- Q3 2024 — Reporting Period (The financial and operational period covered by the 10-Q filing.)
- 2024-09-30 — As of Date (The specific date as of which the financial information is reported.)
- 2024-11-06 — Filing Date (The date the report was officially submitted to the SEC.)
Key Players & Entities
- Alector, Inc. (company) — Filer of the 10-Q report
- 20240930 (date) — End of the reporting period
- 20241106 (date) — Date of filing
- South San Francisco, CA (location) — Company's business address
- GSK (company) — Mentioned in relation to a collaboration or partnership
FAQ
What is the primary business of Alector, Inc.?
Alector, Inc. is primarily involved in the biological products sector, specifically focusing on products without diagnostic substances, as indicated by its SIC code [2836].
When does Alector, Inc.'s fiscal year end?
Alector, Inc.'s fiscal year ends on December 31st.
What is the SEC file number for Alector, Inc.?
The SEC file number for Alector, Inc. is 001-38792.
What is the business address of Alector, Inc.?
The business address of Alector, Inc. is 131 Oyster Point Blvd., Suite 600, South San Francisco, CA 94080.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending September 30, 2024.
From the Filing
0000950170-24-122328.txt : 20241106 0000950170-24-122328.hdr.sgml : 20241106 20241106161521 ACCESSION NUMBER: 0000950170-24-122328 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 241431149 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 10-Q 1 alec-20240930.htm 10-Q 10-Q 365 399 0001653087 --12-31 Q3 false 0001653087 alec:GaryRomanoMember alec:Rule10B51TradingPlanOneMember 2024-09-30 0001653087 alec:GskMember 2021-07-01 2021-07-01 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001653087 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001653087 2024-11-01 0001653087 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001653087 us-gaap:CommonStockMember 2024-06-30 0001653087 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001653087 2024-01-01 2024-09-30 0001653087 alec:OtherOfficerOrDirectorMember 2024-07-01 2024-09-30 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001653087 alec:GskMember 2021-08-17 2021-08-17 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001653087 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001653087 2024-07-01 2024-09-30 0001653087 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001653087 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001653087 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001653087 2024-09-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001653087 us-gaap:RetainedEarningsMember 2023-12-31 0001653087 2023-12-31 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001653087 alec:GskMember 2023-05-01 2023-05-31 0001653087 alec:GskMember 2024-07-01 2024-09-30 0001653087 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001653087 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001653087 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001653087 alec:DrGrassoMember 2024-07-01 2024-09-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001653087 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001653087 2022-12-31 0001653087 alec:GskMember 2022-01-01 2022-01-31 0001653087 2023-09-30 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001653087 alec:MarcGrassoMember alec:Rule10B51TradingPlanMember 2024-09-30 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001653087 alec:CertificateOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001653087 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001653087 us-gaap:OverAllotmentOptionMember 2024-01-19 0001653087 2024-04-01 2024-06-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001653087 2024-03-31 0001653087 us-gaap:Accumulate